Can we stop these cancer drugs without the tumor coming back?
NCT ID NCT07110246
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether patients with a certain type of slow-growing brain tumor (low-grade glioma with a BRAF V600 mutation) can safely stop or reduce their dose of two targeted drugs, dabrafenib and trametinib, after 12-24 months of treatment. About 96 participants will either stop the drugs abruptly or slowly wean off over 6 months. The goal is to see if the tumor stays under control without the full dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dabrafenib and trametinib
What this could lead to
If successful, this could help doctors find the best way to reduce or stop these drugs without causing the tumor to grow back quickly, improving quality of life for patients.
What could go wrong
This is a small, early-phase trial with only 96 participants, so results may not apply to everyone. There is a risk that stopping or reducing the drugs could cause the tumor to regrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact
-
John Hopkins Medical Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Louis Children's Hospital Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
Contact
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
Contact